Testing Genetic Sequencing to Guide Treatment for Drug-resistant Tuberculosis
Tests a genetic sequencing test to guide treatment in people with drug-resistant tuberculosis.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Cape Town, South AfricaSee the site
- Trial code
- Registry title
- Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
- Status
- Recruiting
- People taking part
- 2,500 people, planned
- Started
- 1 Aug 2024
- Expected to end
- Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Targeted next-generation sequencing
- Record updated
- 26 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people diagnosed with active rifampin-resistant tuberculosis at a study facility, with a positive TB test from a sample.
- Sex
- Anyone can join, men and women.
- Disease stage
- Active rifampin-resistant tuberculosis (RR-TB) diagnosed at a study facility during the study period.
- Biomarker or test result
- A positive Mtb culture, smear, or sample derivative (for example a GenoLyse remnant or Xpert cartridge extract).
Main reasons for not taking part
- Expects to move out of the study region
- Does not agree to take part in the study
- Later found to have rifamycin susceptibility on at least two additional tests
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Active RR-TB diagnosed at a study facility during the study period
- Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)
Who cannot take part
- Patient expects to relocate/move residence outside of the study region
- Patient does not agree to participate in the study; In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions
This trial is currently available in South Africa.
- South African National Health Laboratory ServiceCape Town, South AfricaContact: Robin M Warren, PhDTaking people
About the trial
What the trial wants to find out
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
The 2 groups in the trial
- Sequencing Intervention in addition to standard of careTreatment being tested
Batched targeted deep sequencing in addition to the locally accepted standard of care drug susceptibility determination of multidrug/extensively drug-resistant tuberculosis (M/XDR-TB)
Treatment: Targeted next-generation sequencing
- Standard of CareNo study treatment, for comparison
Locally accepted standard of care which is consistent with the WHO recommendations for the drug susceptibility determination of M/XDR-TB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
- Plain-language title
- Testing Genetic Sequencing to Guide Treatment for Drug-resistant TuberculosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 January 2026